Malignant Mesothelioma — Trials

Malignant Mesothelioma — Trials · CancerIndex

Clinical trials

Registered studies

478 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 96
Recruiting: 55
Ph III recruiting: 1
Growth YoY: —
Industry share: 38%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.4%
Trials / 1,000 deaths: 45.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (81)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04158141	Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma	terminated	Phase 3	16	NRG OncologyOTHER	1	Jul 13, 2026	clinicaltrials
NCT01907100	Nintedanib (BIBF 1120) in Mesothelioma	terminated	Phase 2 / Phase 3	545	Boehringer IngelheimINDUSTRY	27	Mar 18, 2019	clinicaltrials